Amylyx Pharmaceuticals, Inc. (AMLX) Return on equity 2022–2025
Amylyx Pharmaceuticals, Inc. (AMLX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-47.4%FY2025 · since FY2022: -58.2% → -47.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -47.4% | +135.7 pp |
| FY2024 | -183.1% | -194.5 pp |
| FY2023 | 11.4% | +69.6 pp |
| FY2022 | -58.2% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice